R-DXd

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Small Cell Lung CancerFallopian Tube CancerSolid Cancer

140 competitors in Small Cell Lung Cancer

#DrugCompanyPhaseTrials

1

Imfinzi

AstraZeneca

Phase 3

292

Tecentriq

Roche

Phase 3

263

Camptosar

Pfizer

Phase 3

264

Keytruda

Merck & Co.

Phase 3

195

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

976

Vepesid

AAvyxa

Phase 3

1087

Opdivo

Bristol-Myers Squibb

Phase 3

148

Tarlatamab-Dznl

Amgen

Phase 3

119

Yervoy

Bristol-Myers Squibb

Phase 3

1110

Lynparza

AstraZeneca

Phase 3

10Show 40 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Ovarian Cancer2 trials

A Phase 3, Open-Label, Multicenter, Randomized Study of Raludotatug Deruxtecan (MK-5909, R-DXd) With or Without Bevacizumab Versus Standard-of-Care Platinum-Based Doublet Chemotherapy With or Without Bevacizumab in Participants With Advanced Platinum-Sensitive High-Grade Serous or High-Grade Endometrioid Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Have Progressed During First-Line PARPi Maintenance (ENGOT-ov107 / GOG-3142 / REJOICE-Ovarian05)

Recruiting·Merck & Co.·Phase 3·NCT07743164·646 enrolled

A Phase 3, Randomized, Open-label Study of Raludotatug Deruxtecan (MK-5909, R-DXd) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care in Participants With Newly-Diagnosed Advanced Non-HRD-Positive Ovarian Cancer Following First-line Platinum-based Chemotherapy (ENGOT-ov102/MITO/GOG-3141/ REJOICE-Ovarian 04)

Recruiting·Merck & Co.·Phase 3·NCT07776691·802 enrolled

Small Cell Lung Cancer1 trial

Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)

Recruiting·Merck & Co.·Phase 1/2·NCT04938817·110 enrolled

Solid Cancer1 trial

A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recruiting·Daiichi Sankyo·Preclinical·NCT06161025·860 enrolled

Lung Neoplasm1 trial

KEYMAKER-U01 Substudy 01I: A Phase 2, Randomized, Umbrella Study With Rolling Arms of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC)

Recruiting·Merck & Co.·Phase 2·NCT06780098·144 enrolled

Fallopian Tube Cancer1 trial

A Phase 3, Multicenter, Randomized, Open-Label Trial of Raludotatug Deruxtecan With or Without Bevacizumab as Maintenance Therapy Versus Standard of Care in Participants With First Recurrence Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (REJOICE-Ovarian03)

Not yet recruiting·Daiichi Sankyo·Phase 3·NCT07791732·600 enrolled

Details

Drug Info

Related News